Nobilon advances first vaccine into human trials
Intranasal influenza vaccine begins Phase I clinical development
16-Mar-2009 -
Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal ...
cell cultures
immunogenicity
vaccines
+1